Symbols

NBP

NovaBridge·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NBP

Novabridge Biosciences

A global biotechnology platform company that focuses on the fields of tumors and autoimmune diseases, committed to promoting China's innovative drugs to go global

Industry

Biological Technology

Established Date

06/30/2016

Listing Date

01/17/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.novabridge.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

2440 Research Boulevard, Suite 400, Rockville, MD 20850, United States

Business

Discover, develop and commercialize new or highly differentiated biological agents

Introduction

Newbridge Bio was incorporated in the Cayman Islands on June 30, 2016. The company is a global biotechnology platform company with a development strategy that is not limited to therapeutic areas. The company's core product, givastomig, is a novel bispecific antibody (' bsAb ') that simultaneously targets the tumor antigen Claudin 18.2 (' CLDN 18.2 '), which is mainly expressed in gastric, esophageal and pancreatic cancer, and the T cell co-stimulating molecule 4-1BB. With the extensive expression of CLDN 18.2 in a variety of tumors, givastomig can target a variety of indications, including gastroesophageal adenocarcinoma (' GEA ', including gastric cancer (' GC '), gastroesophageal junction cancer (' GEJC ') and esophageal adenocarcinoma), bile duct cancer (' BTC ') and pancreatic ductal adenocarcinoma (' PDAC '). According to the Frost & Sullivan Report, the global market size of first-line therapy for GEA, BTC and PDAC (excluding Greater China and Korea) is estimated to be USD 8.9 billion, USD 1.8 billion and USD 4.4 billion respectively in 2024, and is expected to reach USD 13 billion, USD 2.9 billion and USD 6.4 billion respectively by 2034. The company has completed the Phase 1 a portion of the Phase I clinical study and the safety evaluation of the Phase 1 b dose escalation study. A randomized Phase II study will be initiated in early 2026. After submitting the clinical trial protocol in August 2025, the Company has not received any objections or concerns from the U.S. FDA regarding givastomig's Phase II combination therapy trial for CLDN18.2 positive and PD-L1 positive GEA patients. In addition to givastomig, as of the Latest Practicable Date, the Company has established a pipeline of three clinical stage projects, including two oncology projects uliledlimab and ragistomig, and ophthalmology project VIS-101.

Company Financials

EPS

NBP has released its 2025 Q2 earnings. EPS was reported at -0.07, versus the expected -0.05, missing expectations. The chart below visualizes how NBP has performed over recent quarters, highlighting trends in earnings surprises.